Aicardi Syndrome Market Share

Aicardi Syndrome Market Scenario

Aicardi Syndrome market is expected to grow USD 3.4 Billion at a CAGR 5.80% steady pace over the forecast period of 2023–2030. Aicardi syndrome is a rare genetic malformation syndrome characterized by the partial or complete absence of a key structure in the brain called the corpus callosum. The disorder primarily affects females, the mutation specifically occurs on the X chromosome. Symptoms of Aicardi syndrome include rib and spine abnormalities, such as scoliosis. Children with the syndrome may also have unusual facial features, such as larger ears, a flatter nose, or a smaller space between the upper lip and nose. Additionally, Aicardi syndrome can result in poorly developed eyes, impaired vision or blindness. The increasing research activities on rare disorders contribute to the growth of the market. For instance, Aicardi Syndrome Foundation, a non-profit organization contributes to ongoing research of Aicardi syndrome at Baylor University, Texas Children’s Hospital and The University of California, San Francisco.

The rising incidence of Aicardi syndrome, growing prevalence of rare disorders, technological advancements in the medical sector, and growing research and development (R&D) activities, are anticipated to drive the growth of the market during the forecast period.  Despite the driver, the lack of awareness about the syndrome in the developing regions and difficulties in diagnosis may restrain the growth of the Aicardi syndrome market over the forecast period.

Segmentation

The Aicardi syndrome market has been segmented into diagnosis, treatment, and end-user.

The market, based on diagnosis, has been segmented into magnetic resonance imaging (MRI), eye examination, and others.

The market, by treatment, has been segmented into seizure medication, surgery, physical therapy, occupational therapy, speech therapy, vision therapy, and others. The market, by seizure medication, is further segmented into vigabatrin, sodium valproate, and others.

The market, by end-user, has been segmented into hospital and clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Aicardi syndrome market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Aicardi syndrome market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Aicardi syndrome market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Aicardi Syndrome market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Siemens Healthineers, General Electric Company, Koninklijke Philips N.V., Hitachi, Ltd., Canon Medical Systems Europe B.V., Medtronic, Smart Speech Therapy, Therapy Solutions Inc., Carestream Health, Esaote SpA, Lundbeck, and Novartis AG are some of the key players in the Aicardi syndrome market.

Regional Market Summary

Aicardi Syndrome Market Share (%), by Region, 2017

Source: World Health Organization (WHO), Office for National Statistics, National Organization for Rare Disorders

Geographically, the Americas is anticipated to dominate the Aicardi Syndrome market owing to a rising research and development funding for rare diseases, and presence of well-developed healthcare infrastructure. Additionally, increasing healthcare expenditure provides a favorable background for pharmaceutical companies which is thereby expected to contribute to the market growth in the region. According to the Centers for Disease Control and Prevention (CDC), total national health expenditures were USD 3.2 trillion in 2015.

Europe is expected to hold the second largest position in the Aicardi syndrome market. The market growth in this region is attributed to the growing awareness of rare diseases and increasing research and development (R&D) activities. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.

Asia-Pacific is anticipated to be the fastest growing market owing to the growing development in healthcare infrastructure, increasing number of regional expansions by multinational biopharmaceutical companies, and increasing government expenditure for the healthcare sector.

The Middle East & Africa is anticipated to account for the lowest market share in the Aicardi syndrome market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.

Market of Aicardi Syndrome, by Diagnosis

• Magnetic Resonance Imaging (MRI)


• Eye Examination


• Others

Market of Aicardi Syndrome, by Treatment

• Seizure Medication




• Vigabatrin


• Sodium Valproate


• Others




• Surgery


• Physical Therapy


• Occupational Therapy


• Speech Therapy


• Vision therapy


• Others

Market of Aicardi Syndrome, by End-User

• Hospital Clinics


• Diagnostic Centers


• Others

Market of Aicardi Syndrome, by Region

• 
  Americas
  
  
  
  • North America
  
  
  • US
  
  
  • Canada
  
  
  
  


• South America


• 
  Europe
  
  
  
  • Western Europe
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • UK
  
  
  • Rest of Western Europe
  
  
  
  


• Eastern Europe


• 
  Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  The Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Intended Audience

• Pharmaceutical Companies


• Research and Development (R&D) Companies


• Diagnostic Laboratories


• Government Research Institute


• Academic Institutes and Universities